1. Home
  2. AKRO vs ENLT Comparison

AKRO vs ENLT Comparison

Compare AKRO & ENLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKRO
  • ENLT
  • Stock Information
  • Founded
  • AKRO 2017
  • ENLT 2008
  • Country
  • AKRO United States
  • ENLT Israel
  • Employees
  • AKRO N/A
  • ENLT N/A
  • Industry
  • AKRO Biotechnology: Pharmaceutical Preparations
  • ENLT
  • Sector
  • AKRO Health Care
  • ENLT
  • Exchange
  • AKRO Nasdaq
  • ENLT Nasdaq
  • Market Cap
  • AKRO 2.0B
  • ENLT 1.9B
  • IPO Year
  • AKRO 2019
  • ENLT 2023
  • Fundamental
  • Price
  • AKRO $28.08
  • ENLT $17.33
  • Analyst Decision
  • AKRO Strong Buy
  • ENLT Buy
  • Analyst Count
  • AKRO 8
  • ENLT 4
  • Target Price
  • AKRO $46.83
  • ENLT $19.00
  • AVG Volume (30 Days)
  • AKRO 594.3K
  • ENLT 24.1K
  • Earning Date
  • AKRO 02-27-2025
  • ENLT 02-24-2025
  • Dividend Yield
  • AKRO N/A
  • ENLT N/A
  • EPS Growth
  • AKRO N/A
  • ENLT N/A
  • EPS
  • AKRO N/A
  • ENLT 0.41
  • Revenue
  • AKRO N/A
  • ENLT $358,416,000.00
  • Revenue This Year
  • AKRO N/A
  • ENLT $428.35
  • Revenue Next Year
  • AKRO N/A
  • ENLT $27.54
  • P/E Ratio
  • AKRO N/A
  • ENLT $41.89
  • Revenue Growth
  • AKRO N/A
  • ENLT 47.65
  • 52 Week Low
  • AKRO $15.32
  • ENLT $14.09
  • 52 Week High
  • AKRO $37.00
  • ENLT $18.61
  • Technical
  • Relative Strength Index (RSI)
  • AKRO 41.87
  • ENLT 60.95
  • Support Level
  • AKRO $27.45
  • ENLT $16.71
  • Resistance Level
  • AKRO $28.76
  • ENLT $17.34
  • Average True Range (ATR)
  • AKRO 1.49
  • ENLT 0.42
  • MACD
  • AKRO -0.12
  • ENLT 0.12
  • Stochastic Oscillator
  • AKRO 17.98
  • ENLT 83.48

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.

About ENLT Enlight Renewable Energy Ltd.

Enlight Renewable Energy Ltd develops, finances, constructs, owns, and operates utility-scale renewable energy projects. It operates across the three largest renewable segments namely solar, wind and energy storage. Geographically, it operates in the United States, Israel and 9 European countries.

Share on Social Networks: